Ruth B Thornton1, Lea-Ann S Kirkham2, Karli J Corscadden3, Harvey L Coates4, Shyan Vijayasekaran5, Jessica Hillwood6, Sophie Toster7, Phillipa Edminston8, Guicheng Zhang9, Anthony Keil10, Peter C Richmond11. 1. School of Paediatrics and Child Health, The University of Western Australia, GPO Box D184, Perth, Western Australia, 6840, Australia; Telethon Kids Institute, The University of Western Australia, 100 Roberts Road, Subiaco, Western Australia, 6008, Australia. Electronic address: ruth.thornton@uwa.edu.au. 2. School of Paediatrics and Child Health, The University of Western Australia, GPO Box D184, Perth, Western Australia, 6840, Australia; Telethon Kids Institute, The University of Western Australia, 100 Roberts Road, Subiaco, Western Australia, 6008, Australia. Electronic address: lea-ann.kirkham@uwa.edu.au. 3. School of Paediatrics and Child Health, The University of Western Australia, GPO Box D184, Perth, Western Australia, 6840, Australia; Telethon Kids Institute, The University of Western Australia, 100 Roberts Road, Subiaco, Western Australia, 6008, Australia. Electronic address: karli.corscadden@uwa.edu.au. 4. School of Paediatrics and Child Health, The University of Western Australia, GPO Box D184, Perth, Western Australia, 6840, Australia; Telethon Kids Institute, The University of Western Australia, 100 Roberts Road, Subiaco, Western Australia, 6008, Australia; Department of Otorhinolaryngology, Princess Margaret Hospital for Children, Roberts Road, Subiaco, Western Australia, 6008, Australia. Electronic address: harvey.coates@uwa.edu.au. 5. School of Paediatrics and Child Health, The University of Western Australia, GPO Box D184, Perth, Western Australia, 6840, Australia; Telethon Kids Institute, The University of Western Australia, 100 Roberts Road, Subiaco, Western Australia, 6008, Australia; Department of Otorhinolaryngology, Princess Margaret Hospital for Children, Roberts Road, Subiaco, Western Australia, 6008, Australia. Electronic address: shyan_vijayasekaran@me.com. 6. School of Paediatrics and Child Health, The University of Western Australia, GPO Box D184, Perth, Western Australia, 6840, Australia. Electronic address: 20352947@student.uwa.edu.au. 7. School of Paediatrics and Child Health, The University of Western Australia, GPO Box D184, Perth, Western Australia, 6840, Australia. Electronic address: 20348782@student.uwa.edu.au. 8. School of Paediatrics and Child Health, The University of Western Australia, GPO Box D184, Perth, Western Australia, 6840, Australia. Electronic address: 20348263@student.uwa.edu.au. 9. School of Paediatrics and Child Health, The University of Western Australia, GPO Box D184, Perth, Western Australia, 6840, Australia; School of Public Health, Curtin University, GPO Box U1987, Perth, Western Australia, 6845, Australia. Electronic address: guicheng.zhang@uwa.edu.au. 10. PathWest Laboratory Medicine WA, Princess Margaret Hospital for Children, Roberts Road, Subiaco, Western Australia, 6008, Australia. Electronic address: Anthony.Keil@health.wa.gov.au. 11. School of Paediatrics and Child Health, The University of Western Australia, GPO Box D184, Perth, Western Australia, 6840, Australia; Telethon Kids Institute, The University of Western Australia, 100 Roberts Road, Subiaco, Western Australia, 6008, Australia; Department of Otorhinolaryngology, Princess Margaret Hospital for Children, Roberts Road, Subiaco, Western Australia, 6008, Australia. Electronic address: peter.richmond@uwa.edu.au.
Abstract
BACKGROUND: The Australian Aboriginal population experiences disproportionately high rates of otitis media (OM). Streptococcus pneumoniae is one of the main pathogens responsible for OM and currently no vaccine offering cross strain protection exists. Vaccines consisting of conserved antigens to S. pneumoniae may reduce the burden of OM in high-risk populations; however no data exists examining naturally acquired antibody in Aboriginal children with OM. METHODS: Serum and salivary IgA and IgG were measured against the S. pneumoniae antigens PspA1 and 2, CbpA and Ply in a cross sectional study of 183 children, including 36 non-Aboriginal healthy control children and 70 Aboriginal children and 77 non-Aboriginal children undergoing surgery for OM using a multiplex bead assay. RESULTS: Significant differences were observed between the 3 groups for serum anti-PspA1 IgA, anti-CbpA and anti-Ply IgG and for all salivary antibodies assessed. Aboriginal children with a history of OM had significantly higher antibody titres than non-Aboriginal healthy children with no history of OM and non-Aboriginal children with a history of OM for several proteins in serum and saliva. Non-Aboriginal children with a history of OM had significantly higher salivary anti-PspA1 IgG than healthy children, while all other titres were comparable between the groups. CONCLUSIONS: Conserved vaccine candidate proteins from S. pneumoniae induce serum and salivary antibody responses in Aboriginal and non-Aboriginal children with a history of OM. Aboriginal children do not have an impaired antibody response to the antigens measured from S. pneumoniae and they may represent vaccine candidates in Indigenous populations.
BACKGROUND: The Australian Aboriginal population experiences disproportionately high rates of otitis media (OM). Streptococcus pneumoniae is one of the main pathogens responsible for OM and currently no vaccine offering cross strain protection exists. Vaccines consisting of conserved antigens to S. pneumoniae may reduce the burden of OM in high-risk populations; however no data exists examining naturally acquired antibody in Aboriginal children with OM. METHODS: Serum and salivary IgA and IgG were measured against the S. pneumoniae antigens PspA1 and 2, CbpA and Ply in a cross sectional study of 183 children, including 36 non-Aboriginal healthy control children and 70 Aboriginal children and 77 non-Aboriginal children undergoing surgery for OM using a multiplex bead assay. RESULTS: Significant differences were observed between the 3 groups for serum anti-PspA1 IgA, anti-CbpA and anti-Ply IgG and for all salivary antibodies assessed. Aboriginal children with a history of OM had significantly higher antibody titres than non-Aboriginal healthy children with no history of OM and non-Aboriginal children with a history of OM for several proteins in serum and saliva. Non-Aboriginal children with a history of OM had significantly higher salivary anti-PspA1 IgG than healthy children, while all other titres were comparable between the groups. CONCLUSIONS: Conserved vaccine candidate proteins from S. pneumoniae induce serum and salivary antibody responses in Aboriginal and non-Aboriginal children with a history of OM. Aboriginal children do not have an impaired antibody response to the antigens measured from S. pneumoniae and they may represent vaccine candidates in Indigenous populations.
Authors: Kelly M Martinovich; Tasmina Rahman; Camilla de Gier; Elke J Seppanen; Tilda Orami; Caitlyn M Granland; Jacinta Francis; Mition Yoannes; Karli J Corscadden; Rebecca Ford; Peter Jacoby; Anita H J van den Biggelaar; Lauren O Bakaletz; Allan W Cripps; Deborah Lehmann; Peter C Richmond; William S Pomat; Lea-Ann S Kirkham; Ruth B Thornton Journal: Front Immunol Date: 2021-08-10 Impact factor: 7.561
Authors: Ruth B Thornton; Lea-Ann S Kirkham; Karli J Corscadden; Selma P Wiertsema; Angela Fuery; B Jan Jones; Harvey L Coates; Shyan Vijayasekaran; Guicheng Zhang; Anthony Keil; Peter C Richmond Journal: Clin Vaccine Immunol Date: 2017-04-05
Authors: Sharon L Clark; Elke J Seppanen; Lea-Ann S Kirkham; Laura A Novotny; Lauren O Bakaletz; Allan W Cripps; Karli Corscadden; Harvey Coates; Shyan Vijayasekaran; Peter C Richmond; Ruth B Thornton Journal: Front Cell Infect Microbiol Date: 2022-04-07 Impact factor: 6.073
Authors: Camilla de Gier; Caitlyn M Granland; Janessa L Pickering; Tony Walls; Mejbah Bhuiyan; Nikki Mills; Peter C Richmond; Emma J Best; Ruth B Thornton; Lea-Ann S Kirkham Journal: Vaccines (Basel) Date: 2019-01-31
Authors: Tilda Orami; Rebecca Ford; Lea-Ann Kirkham; Ruth Thornton; Karli Corscadden; Peter C Richmond; William S Pomat; Anita H J van den Biggelaar; Deborah Lehmann Journal: Vaccine Date: 2020-10-26 Impact factor: 3.641